株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

日本の体外診断 (IVD) 市場:診断項目、企業、医療費償還、ポーターモデル、成長促進要因、課題、機会

Japan In Vitro Diagnostics (IVD) Market, By Diagnostics, Companies, Reimbursements, Porter's Model, Growth Drivers, Opportunities Challenges

発行 Renub Research 商品コード 711739
出版日 ページ情報 英文 144 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.88円で換算しております。
日本の体外診断 (IVD) 市場:診断項目、企業、医療費償還、ポーターモデル、成長促進要因、課題、機会 Japan In Vitro Diagnostics (IVD) Market, By Diagnostics, Companies, Reimbursements, Porter's Model, Growth Drivers, Opportunities Challenges
出版日: 2020年05月01日 ページ情報: 英文 144 Pages
概要

当レポートでは、日本における体外診断 (IVD) の市場について分析し、市場の基本構造や背景事情・政策環境、市場全体および部門別の動向見通し、市場の促進・抑制要因と求心力、主要企業のプロファイル・業績・戦略などについて調査しております。

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 市場の展望:日本の体外診断 (VD) 市場

第5章 市場シェア分析

第6章 日本のIVD市場:部門別

  • 尿検査
  • 血液検査
  • 臨床化学検査
  • 血糖自己モニタリング
  • 腫瘍マーカー
  • 免疫検査
  • 感染症検査
  • 細菌検査
  • 病理検査
  • 遺伝子検査
  • その他

第7章 ポーターのファイブフォース分析

  • 新規参入企業の脅威
  • バイヤーの交渉力
  • 代替製品の脅威
  • サプライヤーの交渉力
  • 企業間の競合関係

第8章 市場のダイナミクス

  • 成長促進要因
  • 課題
  • 機会

第9章 医療費償還政策

第10章 Abbott Laboratories:企業分析

  • 企業概要
  • 企業戦略の展開状況
  • 財務分析

第11章 Danaher Corporation:企業分析

第12章 Biomerieux:企業分析

第13章 Roche Diagnostics:企業分析

図表

List of Figures

  • Figure-01: Japan- In-vitro Diagnostic Market size (Million US$), 2018 & 2024
  • Figure-02: Japan- In-vitro Diagnostic Top Two Rapid Growing Segment 2020 - 2026
  • Figure-03: Japan- In-vitro Diagnostic Largest Market Share, Immunology (Percent), 2019 -2026
  • Figure-04: Japan- Age-related disease type (Percentage), 2005 - 2016
  • Figure-05: Japan - Healthcare expenditure GDP( Percentage) 2018-2030
  • Figure-06: Japna - Healthcare expenditure market (Billion US$), 2005 - 2025
  • Figure-07: Japan- Government Healthcare Spending for 75 and older Population ( Billion US$), 2015 - 2025
  • Figure-08: Japan - In-vitro Diagnostics Market (Million US$), 2012 - 2019
  • Figure-09: Japan - Forecast for In-vitro Diagnostics Market (Million US$), 2020 - 2026
  • Figure-10: Japan- Urine & Faces Diagnostics Market (Million US$), 2012 - 2019
  • Figure-11: Japan- Forecast for Urine & Faces Diagnostics Market (Million US$), 2020 - 2026
  • Figure-12: Japan- Hematology Market (Million US$), 2012 - 2019
  • Figure-13: Japan- Forecast for Hematology Market (Million US$), 2020 - 2026
  • Figure-14: Japan- Clinical Chemistry Market (Million US$), 2012 - 2019
  • Figure-15: Japan- Forecast for Clinical Chemistry Market (Million US$), 2020 - 2026
  • Figure-16: Japan- SMBG Market (Million US$), 2012 - 2019
  • Figure-17: Japan- Forecast for SMBG Market (Million US$), 2020 - 2026
  • Figure-18: Japan- Tumor Marker Market (Million US$), 2012 - 2019
  • Figure-19: Japan- Forecast for Tumor Marker Market (Million US$), 2020 - 2026
  • Figure-20: Japan- Immunology Market (Million US$), 2012 - 2019
  • Figure-21: Japan- Forecast for Immunology Market (Million US$), 2020 - 2026
  • Figure-22: Japan- Infectious Disease Market (Million US$), 2012 - 2019
  • Figure-23: Japan- Forecast for Infectious Disease Market (Million US$), 2020 - 2026
  • Figure-24: Japan- Microbiology Testing Market (Million US$), 2012 - 2019
  • Figure-25: Japan- Forecast for Microbiology Testing Market (Million US$), 2020 - 2026
  • Figure-26: Japan - Pathology Market (Million US$), 2012 - 2019
  • Figure-27: Japan- Forecast for Pathology Market (Million US$), 2020 - 2026
  • Figure-28: Japan - Genetic Testing Market (Million US$), 2012 - 2019
  • Figure-29: Japan - Forecast for Genetic Testing Market (Million US$), 2020 - 2026
  • Figure-30: Japan- Others Segment Market (Million US$), 2012 - 2019
  • Figure-31: Japan - Forecast for Others Market (Million US$), 2020 - 2026
  • Figure-32: Abbott Laboratories - Global Diagnostic Sales (Million US$), 2015 - 2019
  • Figure-33: Abbott Laboratories - Global Forecast for Diagnostic Sales (Million US$), 2020 - 2026
  • Figure-34: Danaher Corporation - Global Diagnostic Sales (Million US$), 2015 - 2019
  • Figure-35: Danaher Corporation - Global Forecast for Diagnostic Sales (Million US$), 2020 - 2026
  • Figure-36: Biomerieux- Global Diagnostic Sales (Million US$), 2015 - 2019
  • Figure-37: Biomerieux - Global Forecast for Diagnostic Sales (Million US$), 2020 - 2026
  • Figure-38: Roche Diagnostics - Global Diagnostics Division sales (Million US$), 2015 - 2019
  • Figure-39: Roche Diagnostics - Global Forecast for Diagnostics Division sales (Million US$), 2020 - 2026
  • Figure-40: Becton - Global Diagnostics System sales (Million US$), 2015 - 2019
  • Figure-41: Becton - Global Forecast for Diagnostics System sales (Million US$), 2020 - 2026
目次

As most of the industry growth rate in Japan is hit due to COVID-19, but on the contrary, Japan In-Vitro Diagnostics Market is expected to put an exceptional higher growth rate in 2020 compared to its past years (read the report for Coronavirus impact on IVD industry of Japan). According to our research report, Japan In-vitro Diagnostic Market is projected to reach US$ 4.43 Billion by 2026.

In-vitro Diagnostics falls under the medical devices segment, which is used by disposable & consumable, and it is also used in many different, different types of medical tones to find multiple bio-samples. In recent years, several developments have happened in the field of In-vitro diagnostics like conventional diagnostics to new generation gene diagnostics. This has become possible with the advent of new technologies, such as genetic testing, chain reaction (PCR), next-generation sequencing (NGS), and molecular diagnostics.

Factors driving the IVD Market in Japan

In Japan, a quarter of its population age 65 years & above and also has the highest proportion of the aging population across the globe. The main problem faced by the Japanese government in recent years is the rise in the number of an aging population, as the cases of aging diseases are multiplying. Accordingly, the Japanese government has given priority to deal with the aging population, and the government is expected to devote an expanded health budget to aging by 2025. This will boost the future of the Japanese In-Vitro Diagnostics Industry by rising prevalence and increased public expenditure.

Apart from that enhanced diagnostic technology, people's awareness and the subsequent growth in the prevalence of chronic and infectious diseases, a rise in the number of private hospitals, and independent testing laboratories are also some of the other factors that contribute to its market growth. Japan's clinical laboratory markets represent one of the largest and fastest-growing markets among the top ten IVD nation markets in the Asia Pacific regions.

Renub Research report titled "Japan In Vitro Diagnostics (IVD) Market, By Diagnostics (Tumor Marker, Urine & Feces, Clinical Chemistry, Hematology, Self Monitoring of Blood Glucose (SMBG), Immunology, Infectious disease, Microbiology, Pathology and Genetic Testing) Companies (Abbott Laboratories, Danaher Corporation, Biomerieux, Roche Diagnostics, and Becton Dickinson), Reimbursements, Porter's Model, Growth Drivers, Opportunities Challenges" provides a complete analysis of Japan In Vitro Diagnostics (IVD) Market.

All the 11 Segments analysis of Japan In-Vitro Diagnostics Market

In this report, we have provided a complete analysis of 11 segments of the Japan In-vitro Diagnostic market. These segments are as follows Clinical Chemistry, Urine & Feces, Hematology, Tumor Marker, Self Monitoring Blood Glucose (SMBG), Immunology, Infectious disease, Microbiology, Pathology, Genetic Testing, and Others. In these In vitro diagnostics segments, we have done a comprehensive analysis of each segment due to COVID-19 along with separate growth factors for each segment.

Good Reimbursement Policy is expected ill further boost the Market of Japan In Vitro Diagnostics Market

Our report describes the scope and breadth of the reimbursement policies along with the full context. It also provides specific guidance and structure about how it operates and how Japanese authorities implement reimbursement policies. It describes how medical devices are categorized in Japan and which class In vitro diagnostic suits. It includes all medical manufacturers that have been in Japan for the past five years applying for reimbursement approval.

Porter's Five Forces Analysis

This research report provides a compressive study of all the 5 Porter's forces and their significant effect on Japan IVD industry.

BY Segment:

  • Urine & Faces Diagnostics
  • Hematology
  • Clinical Chemistry
  • Self-Blood Glucose Monitoring
  • Tumor Marker
  • Immunology
  • Infectious Testing
  • Microbiology
  • Pathology
  • Genetic Testing
  • Others

All the companies given in the report has been studied from two points

  • Recent Developments
  • Sales Analysis

Company Analysis:

  • Abbott Laboratories
  • Danaher Corporation
  • Biomerieux
  • Roche Diagnostics
  • Becton Dickinson

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summery

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges
  • 4.3 Opportunities

5. Porter's Five Forces Analysis

  • 5.1 Threat of New Entry
  • 5.2 The Bargaining Power of Buyer
  • 5.3 Threat of Substitution
  • 5.4 The Bargaining Power of Supplier
  • 5.5 Competitive Rivalry

6. Reimbursement Policy

7. Japan in Vitro Diagnostics Market

8. Market Share -Japan in Vitro Diagnostics

  • 8.1 By Segment

9. Segments - Japan in Vitro Diagnostics Market

  • 9.1 Urine & Faces Diagnostics
  • 9.2 Hematology
  • 9.3 Clinical Chemistry
  • 9.4 Self-Blood Glucose Monitoring
  • 9.5 Tumor Marker
  • 9.6 Immunology
  • 9.7 Infectious Testing
  • 9.8 Microbiology
  • 9.9 Pathology
  • 9.10 Genetic Testing
  • 9.11 Others

10. Company Analysis

  • 10.1 Abbott Laboratories
    • 10.1.1 Overview
    • 10.1.2 Recent Development/Strategy
    • 10.1.3 Sales
  • 10.2 Danaher Corporation
    • 10.2.1 Overview
    • 10.2.2 Recent Development/Strategy
    • 10.2.3 Sales
  • 10.3 Biomerieux
    • 10.3.1 Overview
    • 10.3.2 Recent Development/Strategy
    • 10.3.3 Sales
  • 10.4 Roche Diagnostics
    • 10.4.1 Overview
    • 10.4.2 Recent Development/Strategy
    • 10.4.3 Sales
  • 10.5 Becton
    • 10.5.1 Overview
    • 10.5.2 Recent Development/Strategy
    • 10.5.3 Sales